{"url_path":"/sec/autl/8-k/2026-06-29/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000072-index.html","accession_number":"0001730463-26-000072","cik":"0001730463","ticker":"AUTL","issuer_name":"Autolus Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1730463/0001730463-26-000072-index.html","primary_entity_key":"0001730463","primary_entity_name":"Autolus Therapeutics plc"},"word_count":372,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn June 29, 2026, Autolus Therapeutics plc (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “AGM”). The shareholders considered the six resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 5, 2026 (the “Proxy Statement”). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution.\n\nOrdinary Resolutions\n\nResolution 1: To receive and adopt the Company’s accounts for the financial year ended 31 December 2025 and the associated reports of the Directors and auditors (the “2025 Annual Report and Accounts”). The votes were cast as follows:\n\nForAgainstAbstain\n\n165,846,3262,895,34475,901\n\nResolution 2: To approve the Directors’ remuneration report (excluding the Directors’ remuneration policy), as set out on pages 38 to 67 of the 2025 Annual Report and Accounts. The votes were cast as follows:\n\nForAgainstAbstain\n\n156,192,21612,502,946122,409\n\nResolution 3: To appoint Ernst & Young LLP (US) as auditors of the Company to hold office from the conclusion of the 2026 AGM until the conclusion of the 2027 AGM and to authorize the Directors to determine the auditors’ remuneration. The votes were cast as follows:\n\nForAgainstAbstain\n\n165,871,3682,872,22573,978\n\nResolution 4: To re-elect Mr. M Bonney as a Director. The votes were cast as follows:\n\nForAgainstAbstain\n\n165,491,3943,312,12614,051\n\nResolution 5: To re-elect Dr. E Leiderman as a Director. The votes were cast as follows:\n\nForAgainstAbstain\n\n165,741,2043,063,83812,529\n\nResolution 6: To re-elect Mr. RW Azelby as a Director. The votes were cast as follows:\n\nForAgainstAbstain\n\n162,133,0916,671,77612,704\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nAUTOLUS THERAPEUTICS PLC\n\nDated: June 29, 2025By:/s/Christian Itin, Ph.D.\n\nName: Christian Itin, Ph.D.\n\nTitle: Chief Executive Officer"}